Increased Expression of Angiotensin II Type 1 Receptor (AGTR1) in Heart Transplant Recipients With Recurrent Rejection

Mohamad H. Yamani, Daniel J. Cook, E. Rene Rodriguez, Dawn M. Thomas, Sandeep Gupta, Joan Alster, David O. Taylor, Robert Hobbs, James B. Young, Nicholas Smedira, Randall C. Starling

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: Angiotensin II receptor sub-type 1 (AGTR1) plays an important role in the regulation of the cellular immune process. We hypothesized that recurrent acute rejection is associated with increased gene expression of AGTR1 in human heart transplantation. Methods: We identified a group of 14 heart transplant recipients who had recurrent acute cellular rejection (RAR), defined as three consecutive episodes of acute rejection (Grade ≥3A). These patients were matched to a control group (n = 15). mRNA gene expression of AGTR1 was measured in heart biopsy specimens of controls at 1 week post-transplant. AGTR1 mRNA was determined serially in the RAR group at baseline, each rejection episode, and after resolution of rejection. Angiotensin-converting enzyme (ACE) polymorphism was also evaluated. Results: Both the control and RAR groups had similar mRNA AGTR1 expression at baseline. Compared with baseline, the RAR group had significantly increased mRNA expression of AGTR1 at the first episode of rejection (9-fold, p < 0.001), which increased further at the second episode (12-fold, p < 0.001) and peaked at the third episode (35-fold, p < 0.001). After resolution of rejection, AGTR1 expression was decreased significantly (p < 0.001), but remained elevated above baseline (6-fold, p < 0.001). No difference in ACE polymorphism was noted between the two groups. Compared with controls, the RAR patients had an increased incidence of hypertension, diabetes mellitus, chronic renal insufficiency and transplant vasculopathy during a mean follow-up period of 51.5 ± 12 months. Conclusions: This is the first report to describe increased mRNA expression of AGTR1 in response to recurrent cellular rejection. Up-regulation of AGTR1 responds to treatment of rejection but not to complete recovery, a phenomenon that may potentially explain the link between rejection and subsequent clinical outcome.

Original languageEnglish (US)
Pages (from-to)1283-1289
Number of pages7
JournalJournal of Heart and Lung Transplantation
Volume25
Issue number11
DOIs
StatePublished - Nov 2006
Externally publishedYes

Fingerprint

Angiotensin Type 1 Receptor
Messenger RNA
Peptidyl-Dipeptidase A
Transplants
Gene Expression
Heart Transplantation
Chronic Renal Insufficiency
Diabetes Mellitus
Up-Regulation
Transplant Recipients
Hypertension
Biopsy
Control Groups
Incidence

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine
  • Transplantation

Cite this

Increased Expression of Angiotensin II Type 1 Receptor (AGTR1) in Heart Transplant Recipients With Recurrent Rejection. / Yamani, Mohamad H.; Cook, Daniel J.; Rodriguez, E. Rene; Thomas, Dawn M.; Gupta, Sandeep; Alster, Joan; Taylor, David O.; Hobbs, Robert; Young, James B.; Smedira, Nicholas; Starling, Randall C.

In: Journal of Heart and Lung Transplantation, Vol. 25, No. 11, 11.2006, p. 1283-1289.

Research output: Contribution to journalArticle

Yamani, MH, Cook, DJ, Rodriguez, ER, Thomas, DM, Gupta, S, Alster, J, Taylor, DO, Hobbs, R, Young, JB, Smedira, N & Starling, RC 2006, 'Increased Expression of Angiotensin II Type 1 Receptor (AGTR1) in Heart Transplant Recipients With Recurrent Rejection', Journal of Heart and Lung Transplantation, vol. 25, no. 11, pp. 1283-1289. https://doi.org/10.1016/j.healun.2006.09.012
Yamani, Mohamad H. ; Cook, Daniel J. ; Rodriguez, E. Rene ; Thomas, Dawn M. ; Gupta, Sandeep ; Alster, Joan ; Taylor, David O. ; Hobbs, Robert ; Young, James B. ; Smedira, Nicholas ; Starling, Randall C. / Increased Expression of Angiotensin II Type 1 Receptor (AGTR1) in Heart Transplant Recipients With Recurrent Rejection. In: Journal of Heart and Lung Transplantation. 2006 ; Vol. 25, No. 11. pp. 1283-1289.
@article{78213f50efc6457c8589bc9ea8631805,
title = "Increased Expression of Angiotensin II Type 1 Receptor (AGTR1) in Heart Transplant Recipients With Recurrent Rejection",
abstract = "Background: Angiotensin II receptor sub-type 1 (AGTR1) plays an important role in the regulation of the cellular immune process. We hypothesized that recurrent acute rejection is associated with increased gene expression of AGTR1 in human heart transplantation. Methods: We identified a group of 14 heart transplant recipients who had recurrent acute cellular rejection (RAR), defined as three consecutive episodes of acute rejection (Grade ≥3A). These patients were matched to a control group (n = 15). mRNA gene expression of AGTR1 was measured in heart biopsy specimens of controls at 1 week post-transplant. AGTR1 mRNA was determined serially in the RAR group at baseline, each rejection episode, and after resolution of rejection. Angiotensin-converting enzyme (ACE) polymorphism was also evaluated. Results: Both the control and RAR groups had similar mRNA AGTR1 expression at baseline. Compared with baseline, the RAR group had significantly increased mRNA expression of AGTR1 at the first episode of rejection (9-fold, p < 0.001), which increased further at the second episode (12-fold, p < 0.001) and peaked at the third episode (35-fold, p < 0.001). After resolution of rejection, AGTR1 expression was decreased significantly (p < 0.001), but remained elevated above baseline (6-fold, p < 0.001). No difference in ACE polymorphism was noted between the two groups. Compared with controls, the RAR patients had an increased incidence of hypertension, diabetes mellitus, chronic renal insufficiency and transplant vasculopathy during a mean follow-up period of 51.5 ± 12 months. Conclusions: This is the first report to describe increased mRNA expression of AGTR1 in response to recurrent cellular rejection. Up-regulation of AGTR1 responds to treatment of rejection but not to complete recovery, a phenomenon that may potentially explain the link between rejection and subsequent clinical outcome.",
author = "Yamani, {Mohamad H.} and Cook, {Daniel J.} and Rodriguez, {E. Rene} and Thomas, {Dawn M.} and Sandeep Gupta and Joan Alster and Taylor, {David O.} and Robert Hobbs and Young, {James B.} and Nicholas Smedira and Starling, {Randall C.}",
year = "2006",
month = "11",
doi = "10.1016/j.healun.2006.09.012",
language = "English (US)",
volume = "25",
pages = "1283--1289",
journal = "Journal of Heart and Lung Transplantation",
issn = "1053-2498",
publisher = "Elsevier USA",
number = "11",

}

TY - JOUR

T1 - Increased Expression of Angiotensin II Type 1 Receptor (AGTR1) in Heart Transplant Recipients With Recurrent Rejection

AU - Yamani, Mohamad H.

AU - Cook, Daniel J.

AU - Rodriguez, E. Rene

AU - Thomas, Dawn M.

AU - Gupta, Sandeep

AU - Alster, Joan

AU - Taylor, David O.

AU - Hobbs, Robert

AU - Young, James B.

AU - Smedira, Nicholas

AU - Starling, Randall C.

PY - 2006/11

Y1 - 2006/11

N2 - Background: Angiotensin II receptor sub-type 1 (AGTR1) plays an important role in the regulation of the cellular immune process. We hypothesized that recurrent acute rejection is associated with increased gene expression of AGTR1 in human heart transplantation. Methods: We identified a group of 14 heart transplant recipients who had recurrent acute cellular rejection (RAR), defined as three consecutive episodes of acute rejection (Grade ≥3A). These patients were matched to a control group (n = 15). mRNA gene expression of AGTR1 was measured in heart biopsy specimens of controls at 1 week post-transplant. AGTR1 mRNA was determined serially in the RAR group at baseline, each rejection episode, and after resolution of rejection. Angiotensin-converting enzyme (ACE) polymorphism was also evaluated. Results: Both the control and RAR groups had similar mRNA AGTR1 expression at baseline. Compared with baseline, the RAR group had significantly increased mRNA expression of AGTR1 at the first episode of rejection (9-fold, p < 0.001), which increased further at the second episode (12-fold, p < 0.001) and peaked at the third episode (35-fold, p < 0.001). After resolution of rejection, AGTR1 expression was decreased significantly (p < 0.001), but remained elevated above baseline (6-fold, p < 0.001). No difference in ACE polymorphism was noted between the two groups. Compared with controls, the RAR patients had an increased incidence of hypertension, diabetes mellitus, chronic renal insufficiency and transplant vasculopathy during a mean follow-up period of 51.5 ± 12 months. Conclusions: This is the first report to describe increased mRNA expression of AGTR1 in response to recurrent cellular rejection. Up-regulation of AGTR1 responds to treatment of rejection but not to complete recovery, a phenomenon that may potentially explain the link between rejection and subsequent clinical outcome.

AB - Background: Angiotensin II receptor sub-type 1 (AGTR1) plays an important role in the regulation of the cellular immune process. We hypothesized that recurrent acute rejection is associated with increased gene expression of AGTR1 in human heart transplantation. Methods: We identified a group of 14 heart transplant recipients who had recurrent acute cellular rejection (RAR), defined as three consecutive episodes of acute rejection (Grade ≥3A). These patients were matched to a control group (n = 15). mRNA gene expression of AGTR1 was measured in heart biopsy specimens of controls at 1 week post-transplant. AGTR1 mRNA was determined serially in the RAR group at baseline, each rejection episode, and after resolution of rejection. Angiotensin-converting enzyme (ACE) polymorphism was also evaluated. Results: Both the control and RAR groups had similar mRNA AGTR1 expression at baseline. Compared with baseline, the RAR group had significantly increased mRNA expression of AGTR1 at the first episode of rejection (9-fold, p < 0.001), which increased further at the second episode (12-fold, p < 0.001) and peaked at the third episode (35-fold, p < 0.001). After resolution of rejection, AGTR1 expression was decreased significantly (p < 0.001), but remained elevated above baseline (6-fold, p < 0.001). No difference in ACE polymorphism was noted between the two groups. Compared with controls, the RAR patients had an increased incidence of hypertension, diabetes mellitus, chronic renal insufficiency and transplant vasculopathy during a mean follow-up period of 51.5 ± 12 months. Conclusions: This is the first report to describe increased mRNA expression of AGTR1 in response to recurrent cellular rejection. Up-regulation of AGTR1 responds to treatment of rejection but not to complete recovery, a phenomenon that may potentially explain the link between rejection and subsequent clinical outcome.

UR - http://www.scopus.com/inward/record.url?scp=33750614111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750614111&partnerID=8YFLogxK

U2 - 10.1016/j.healun.2006.09.012

DO - 10.1016/j.healun.2006.09.012

M3 - Article

C2 - 17097490

AN - SCOPUS:33750614111

VL - 25

SP - 1283

EP - 1289

JO - Journal of Heart and Lung Transplantation

JF - Journal of Heart and Lung Transplantation

SN - 1053-2498

IS - 11

ER -